Development of an Ultrasound Technique to Evaluate the Popliteal Complex in the Horse.

The popliteal tendon and muscle are major stabilizers of the human and dog knee, more specifically the postero-lateral corner. Injury to this complex causes posterior knee pain, and it is generally associated with other injured structures such as the lateral collateral ligament, lateral meniscus, and/or the cranial cruciate ligament. The popliteal complex is poorly reported in the horse, and its specific function has not been determined.

Case Report of a Complex Lateral Femorotibial Joint Injury With Popliteal Tendonitis in a Foal.

A two-month-old, Spanish breed, foal was referred with right hind limb lameness of two weeks duration. Clinical examinations confirmed a complex combination of lesions within the lateral femorotibial joint, including a subchondral bone cyst in the lateral femoral condyle, a severe popliteal tendonitis, and a delayed cartilage detachment of the lateral femoral condyle. Because of the complex association of these lesions, poor prognosis for an athletic career was given to the owner.

Small Intestine Ultrasound Findings on Horses Following Exploratory Laparotomy, Can We Predict Postoperative Reflux?

Postoperative reflux (POR) is a well-recognized complication after colic surgery in horses, particularly when presenting small intestinal pathology. Even though much has been written about the pathophysiology and management of POR, additional clinical studies are needed to better understand and anticipate this complication. The aim of the study was to provide clinical evidence of ultrasound findings in the postoperative period (three days).

Anatomical variations of the equine popliteal tendon.

The function of the popliteal muscle and tendon in horses remains undescribed. In humans, it is considered a stabilizer of the posterior-lateral region of the knee; its function is closely related to that of the lateral collateral ligament (LCL) and meniscus. The popliteal tendon (PopT) constitutes the main proximal attachment of the popliteus muscle to the femur, and in humans, insertional variations have been described.

Small-molecule inhibitors prevent the genotoxic and protumoural effects induced by colibactin-producing bacteria.

Objective: Colorectal cancers (CRCs) are frequently colonised by colibactin toxin-producing Escherichia coli bacteria that induce DNA damage in host cells and exhibit protumoural activities. Our objective was to identify small molecules inhibiting the toxic effects induced by these colibactin-producing bacteria.

Design: A structural approach was adopted for the identification of a putative ligand for the ClbP enzyme involved in the synthesis of colibactin.

Maternally acquired genotoxic Escherichia coli alters offspring's intestinal homeostasis.

The neonatal gut is rapidly colonized by a newly dominant group of commensal Escherichia coli strains among which a large proportion produces a genotoxin called colibactin. In order to analyze the short- and long-term effects resulting from such evolution, we developed a rat model mimicking the natural transmission of E. coli from mothers to neonates.

The genotoxin colibactin exacerbates lymphopenia and decreases survival rate in mice infected with septicemic Escherichia coli.

Sepsis is a life-threatening infection. Escherichia coli is the first known cause of bacteremia leading to sepsis. Lymphopenia was shown to predict bacteremia better than conventional markers of infection.

Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells.

Escherichia coli is a normal inhabitant of the human gut. However, E. coli strains of phylogenetic group B2 harbor a genomic island called "pks" that codes for the production of a polyketide-peptide genotoxin, Colibactin.

The role of fibroblast growth factor 21 (FGF21) on energy balance, glucose and lipid metabolism.

FGF21 is a novel member of the FGFs family, is mainly expressed in liver and it functions as a potent activator of glucose uptake on adipocytes. When over expressed in transgenic mice, it protects animals from diet-induced obesity and its administration to diabetic rodents and monkeys lowers blood glucose and triglyceride levels. Recently, increased levels of FGF21 have been identified as an independent risk factor related with metabolic syndrome.